Serina Therapeutics, Inc. (SER)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Research and Development of Its POZ Platform	3.15M	591.50K	3.46M
Research and Development of Its POZ Platform Growth	433.05%	-82.93%	-
Total	3.15M	591.50K	3.46M
Total Growth	433.05%	-82.93%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
United States	3.15M	591.50K	3.46M
United States Growth	433.05%	-82.93%	-
Total	3.15M	591.50K	3.46M
Total Growth	433.05%	-82.93%	-

Source: S&P Global Market Intelligence.